Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Breast Cancer
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Breast Cancer
    Annual Report Finds Declines in Cancer Incidence and Death in US, But Wide Variation in Lung Cancer Trends - (DGNews)
    TopAbstracts in Breast Cancer 11/25/2008 - (DGNews)
    Mammogram Most Effective 12 Months After Radiation Treatment - (DGNews)
    Mammograms May Detect Some Cancers That Would Have Otherwise Regressed - (DGNews)
    Type of Breast Reconstruction Impacts Radiation Therapy Outcomes - (DGNews)

    News archive

     Recent webcasts/CME - Breast Cancer

    Webcasts/CME archive

     Recent cases - Breast Cancer
      Mucinous Breast Carcinoma Presenting as Paget's Disease of the Nipple in a Man: A Case Report
      Presentation and Course of Brain Metastases from Breast Cancer in a Paranoid-Schizophrenic Patient: A Case Report
      Granular Cell Tumour of the Pectoral Muscle Mimicking Breast Cancer
      Primary Osteosarcoma of the Breast: Case Report
      A Case of Matrix-Producing Carcinoma of the Breast

      Cases archive
        




      my personal edition > breast cancer > news
      divider

        E-Mail this DGReview to a colleague

      DGReview


      Fulvestrant Comparable to Tamoxifen in Women with Hormone Receptor-Positive Breast Cancers

      A DGReview of :"Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial"
      Journal of Clinical Oncology (JCO)

      05/20/2004
      By Emma Hitt, PhD


      Fulvestrant appears to be comparable to tamoxifen and the 2 therapies may also be similarly effective in a subgroup of women with hormone receptor-positive breast cancers, a new study suggests.

      Fulvestrant (Faslodex; AstraZeneca Pharmaceuticals LP, Wilmington, DE) is the first of a new type of oestrogen receptor (ER) antagonist that downregulates the ER. In contrast to tamoxifen, fulvestrant appears to be devoid of partial agonist properties.

      Anthony Howell, MD, with the Christie Hospital and Holt Radium Institute, in Manchester, United Kingdom and colleagues evaluated the efficacy and tolerability of fulvestrant for the treatment of advanced breast cancer in postmenopausal women.

      Patients with metastatic/locally advanced breast cancer previously untreated for advanced disease were randomised to receive either fulvestrant, 250 mg, via intramuscular injection, once monthly (n = 313) or tamoxifen 20 mg, orally, once daily (n = 274).


      All tumours were positive for ER (ER+) and/or progesterone receptor (PgR+), or had an unknown receptor status.

      After a median follow-up of 14.5 months, both treatment groups were similar in terms of time to progression (TTP; median TTP, 6.8 months and 8.3 months, respectively; hazard ratio, 1.18; 95% CI, 0.98 to 1.44; P = .088).

      Furthermore, approximately 78% of the patients had known ER+ and/or PgR+ tumours. In these patients, median TTP was 8.2 months for fulvestrant and 8.3 months for tamoxifen (hazard ratio, 1.10; 95% CI, 0.89 to 1.36; P =.39).

      According to the researchers, the overall objective response rate was 31.6% with fulvestrant and 33.9% with tamoxifen whereas in the known hormone receptor-positive subgroup, objective response rate was 33.2% and 31.1%, respectively.

      Both treatments were well tolerated. A total of 129 patients in the fulvestrant group (41.6%) and 139 patients in the tamoxifen group (51.3%) experienced drug-related adverse events. The most frequent drug-related adverse events were vasodilatation, injection-site pain, and nausea for both treatments.

      "Since these drugs work by different mechanisms and are not cross-resistant, they can be used in conjunction with all other endocrine therapies to provide lengthy disease control before more toxic chemotherapy is initiated," Dr. Howell and colleagues conclude.

      Further clinical trials are planned to investigate whether use of a loading regimen of fulvestrant may further improve efficacy. An additional first-line trial of fulvestrant versus anastrozole is also planned, they note.



      J Clin Oncol 2004;22:1605-13. "Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial"

      E-Mail this DGReview to a colleague   To print, use this version






      All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send